Abstract

Parkinson’s disease (PD) is a neurodegenerative disease with unknown cause in the majority of patients, who are therefore considered “idiopathic” (IPD). PD predominantly affects dopaminergic neurons in the substantia nigra pars compacta (SNpc), yet the pathology is not limited to this cell type. Advancing age is considered the main risk factor for the development of IPD and greatly influences the function of microglia, the immune cells of the brain. With increasing age, microglia become dysfunctional and release pro-inflammatory factors into the extracellular space, which promote neuronal cell death. Accordingly, neuroinflammation has also been described as a feature of PD. So far, studies exploring inflammatory pathways in IPD patient samples have primarily focused on blood-derived immune cells or brain sections, but rarely investigated patient microglia in vitro. Accordingly, we decided to explore the contribution of microglia to IPD in a comparative manner using, both, iPSC-derived cultures and postmortem tissue. Our meta-analysis of published RNAseq datasets indicated an upregulation of IL10 and IL1B in nigral tissue from IPD patients. We observed increased expression levels of these cytokines in microglia compared to neurons using our single-cell midbrain atlas. Moreover, IL10 and IL1B were upregulated in IPD compared to control microglia. Next, to validate these findings in vitro, we generated IPD patient microglia from iPSCs using an established differentiation protocol. IPD microglia were more readily primed as indicated by elevated IL1B and IL10 gene expression and higher mRNA and protein levels of NLRP3 after LPS treatment. In addition, IPD microglia had higher phagocytic capacity under basal conditions—a phenotype that was further exacerbated upon stimulation with LPS, suggesting an aberrant microglial function. Our results demonstrate the significance of microglia as the key player in the neuroinflammation process in IPD. While our study highlights the importance of microglia-mediated inflammatory signaling in IPD, further investigations will be needed to explore particular disease mechanisms in these cells.

Highlights

  • Parkinson’s disease (PD) is an age-related, multifactorial disorder, resulting in the demise of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain, which subsequently leads to motor difficulties, tremor, and postural instability in affected individuals (Pang et al, 2019)

  • The transcriptomics data of human IPD and control SN revealed a significant increase in IL1B and IL10 expression in the patient tissue (FDR = 0.023; FDR = 0.0067, respectively) (Figure 1A and Supplementary Table 1)

  • We investigated Leucine-rich repeat kinase 2 (LRRK2) protein levels in our iPSC-derived microglia and saw a non-significant downregulation in untreated IPD microglia compared to controls (CTR mean: 1.332, SD = 0.257; IPD mean: 0.615, SD = 0.425; ANOVA: p = 0.0593)

Read more

Summary

Introduction

Parkinson’s disease (PD) is an age-related, multifactorial disorder, resulting in the demise of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain, which subsequently leads to motor difficulties, tremor, and postural instability in affected individuals (Pang et al, 2019). The majority of studies published to date describe molecular mechanisms centered around α-synuclein aggregation, mitochondrial dysfunction, dysregulated autophagy flux, and neuroinflammation as the underlying causes of PD (Wang et al, 2015; Maiti et al, 2017). All of these processes are affected by aging, which leads to functional decline, both at the physiological and molecular level. On the other hand, during prolonged inflammation, beneficial mechanisms of defense start to wear off while damaging insults increase This phenomenon might explain why seemingly low-grade inflammatory occurrences can have a significant negative impact on health in older individuals (Calabrese et al, 2018)

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call